# Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine

Study · id `cardio:ct-nct05850091` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05850091](<https://clinicaltrials.gov/study/NCT05850091>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05850091

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 200 participants.

## Technical summary

Registry record NCT05850091. Randomized; quadruple masking; primary purpose treatment. Start 2023-12-07 (actual); primary completion 2027-06-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT05850091, source copy `cardio:ctgov-nct05850091-2026-06-12`, retrieved 2026-10-26)
- Started: 2023-12-07 (actual) (ClinicalTrials.gov record NCT05850091, source copy `cardio:ctgov-nct05850091-2026-06-12`, retrieved 2026-10-26)
- Primary completion: 2027-06-01 (anticipated) (ClinicalTrials.gov record NCT05850091, source copy `cardio:ctgov-nct05850091-2026-06-12`, retrieved 2026-10-26)
- Completion: 2027-06-01 (anticipated) (ClinicalTrials.gov record NCT05850091, source copy `cardio:ctgov-nct05850091-2026-06-12`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT05850091, source copy `cardio:ctgov-nct05850091-2026-06-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05850091-2026-06-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine
- Acronym: PROACT 2
- Condition: Coronary Artery Disease
- Intervention (Drug): Rosuvastatin
- Intervention (Drug): Colchicine
- Intervention (Drug): Placebo
- Lead sponsor: Massachusetts General Hospital
- Lead sponsor class: OTHER
- Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record: Rosuvastatin (`cardio:rosuvastatin`)
- Registry intervention name matches this record: Colchicine (`cardio:colchicine`)
- Registry lists this organization as the lead sponsor: Massachusetts General Hospital (`cardio:org-massachusetts-general-hospital`)
- Registry lists this organization as a collaborator: National Heart, Lung, and Blood Institute (`cardio:nhlbi`)

## Provenance

Content hash: db7e6ddc0abbf49809cc119bf56820500928b2cce4f0733bcfdaf54930b1c93c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
